CN104306959B - 一种治疗骨质疏松的药物组合物及其制备方法 - Google Patents
一种治疗骨质疏松的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN104306959B CN104306959B CN201410545155.3A CN201410545155A CN104306959B CN 104306959 B CN104306959 B CN 104306959B CN 201410545155 A CN201410545155 A CN 201410545155A CN 104306959 B CN104306959 B CN 104306959B
- Authority
- CN
- China
- Prior art keywords
- fine powder
- extract
- pharmaceutical composition
- parts
- rhizoma drynariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 230000001009 osteoporotic effect Effects 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 49
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 46
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 30
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 23
- 102000008186 Collagen Human genes 0.000 claims abstract description 22
- 108010035532 Collagen Proteins 0.000 claims abstract description 22
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 21
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims description 58
- 239000003814 drug Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 241000219780 Pueraria Species 0.000 claims 1
- 235000014103 egg white Nutrition 0.000 claims 1
- 210000000969 egg white Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 55
- 208000001132 Osteoporosis Diseases 0.000 abstract description 24
- 230000037182 bone density Effects 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 230000005856 abnormality Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000011575 calcium Substances 0.000 description 32
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 31
- 229910052791 calcium Inorganic materials 0.000 description 31
- 241000700159 Rattus Species 0.000 description 30
- 210000001672 ovary Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000037396 body weight Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000010298 pulverizing process Methods 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004409 osteocyte Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 239000009557 Bak Foong Pill Substances 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- OIIHTRLQCQVVQC-OBQKJFGGSA-N Hydroxystenozole Chemical compound C1CC2=CC=3NN=CC=3C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 OIIHTRLQCQVVQC-OBQKJFGGSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- -1 Zhu Huang San Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229950002179 hydroxystenozole Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000009112 niuhuang Substances 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | |
胶原蛋白 | 20 | 23 | 25 | 29 | 30 |
硫酸软骨素钠盐 | 25 | 22 | 20 | 17 | 15 |
碳酸钙 | 270 | 260 | 250 | 240 | 230 |
骨碎补提取物 | 60 | 64 | 65 | 61 | 60 |
葛根提取物 | 40 | 36 | 35 | 32 | 30 |
D-氨基葡萄糖盐酸盐 | 50 | 53 | 55 | 58 | 60 |
三七 | 60 | 58 | 50 | 45 | 40 |
性状 | 总皂苷含量 | |
JSDL-60A | 白色粉末 | 25.6g/100g |
JSDL-55kw | 白色粉末 | 25.0/100g |
性状 | 总皂苷含量 | |
常温 | 白色粉末 | 20.6g/100g |
0度 | 白色粉末 | 25.3/100g |
-10度 | 白色粉末 | 25.5/100g |
总皂苷含量(g/100g) | 目数 |
19.3 | 300 |
25.3 | 500 |
25.5 | 800 |
26.8 | 1000 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410545155.3A CN104306959B (zh) | 2014-10-16 | 2014-10-16 | 一种治疗骨质疏松的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410545155.3A CN104306959B (zh) | 2014-10-16 | 2014-10-16 | 一种治疗骨质疏松的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104306959A CN104306959A (zh) | 2015-01-28 |
CN104306959B true CN104306959B (zh) | 2016-08-24 |
Family
ID=52362368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410545155.3A Active CN104306959B (zh) | 2014-10-16 | 2014-10-16 | 一种治疗骨质疏松的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104306959B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104799280A (zh) * | 2015-04-10 | 2015-07-29 | 山东安然纳米实业发展有限公司 | 一种具有增强免疫力、增加骨密度功能的保健食品 |
JP6742575B2 (ja) * | 2015-07-02 | 2020-08-19 | 株式会社東洋新薬 | 関節機能改善組成物 |
CN105169372A (zh) * | 2015-09-01 | 2015-12-23 | 南京贝杉国际贸易有限公司 | 一种增加骨密度改善骨质疏松的功能食品及其制备方法 |
CN106729599B (zh) * | 2015-11-25 | 2020-06-23 | 浙江爱生药业有限公司 | 一种增加骨密度的药物组合物及其制备方法和用途 |
CN105639620A (zh) * | 2015-12-29 | 2016-06-08 | 崔俊昌 | 一种增加骨密度的保健食品组合物及其制备方法 |
CN105727249A (zh) * | 2016-03-24 | 2016-07-06 | 河南牧业经济学院 | 治疗猫、犬关节病症的外用膏剂及其制备方法 |
CN106729646A (zh) * | 2016-12-28 | 2017-05-31 | 福州东星生物技术有限公司 | 一种防治骨质疏松的复方制剂 |
JP6744673B2 (ja) * | 2019-06-04 | 2020-08-19 | 株式会社東洋新薬 | 関節機能改善組成物 |
CN110558561A (zh) * | 2019-09-30 | 2019-12-13 | 青岛琛蓝医药科技发展有限公司 | 一种具有促进骨关节健康作用的复方组合物及其应用 |
CN114651980A (zh) * | 2022-03-29 | 2022-06-24 | 马玉芝 | 增加更年期女性骨密度的组合物、制剂及制备方法 |
CN115737729B (zh) * | 2022-11-24 | 2023-11-03 | 新疆医科大学 | 一种治疗骨质疏松的民族药制剂及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1907316A (zh) * | 2005-08-02 | 2007-02-07 | 孙毅 | 一种预防和治疗骨科疾病的药物组合物 |
CN103083650B (zh) * | 2013-03-04 | 2014-12-24 | 中哈福生物医药科技(上海)有限公司 | 一种具有增加骨密度功能的组合物及其制备方法和用途 |
-
2014
- 2014-10-16 CN CN201410545155.3A patent/CN104306959B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104306959A (zh) | 2015-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104306959B (zh) | 一种治疗骨质疏松的药物组合物及其制备方法 | |
JP2006515615A (ja) | 前立腺症状のための薬草組成物 | |
CN104873624A (zh) | 一种用于痛风性关节炎的药物组合物 | |
CN101966222A (zh) | 一种具有壮骨功效的药物组合物、制剂及其制备方法 | |
CN103721242A (zh) | 一种药物组合物在预防或治疗骨质疏松中的新用途 | |
CN104547750A (zh) | 一种治疗老年性骨质疏松症的中药组合物 | |
CN104721678A (zh) | 高良姜提取物在制备抗骨质疏松保健食品及药品方面的应用 | |
CN1706463A (zh) | 一种治疗妇科习惯性流产和先兆性流产疾病的药物 | |
CN102266415B (zh) | 一种复方中药在防治骨质疏松疾病中的应用 | |
CN105998652A (zh) | 一种中药组合物、其应用与一种制剂 | |
CN1209133C (zh) | 防治佝偻病和骨质疏松症的药物及其制备方法 | |
CN101128210B (zh) | 熟地黄和五加皮的草药混合物提取物以及用于预防和治疗骨质疏松症的包含其的组合物 | |
CN103272119A (zh) | 一种用于治疗骨质疏松的中药制剂 | |
CN102283877A (zh) | 一种人参皂苷的应用 | |
CN109820918A (zh) | 一种治疗排卵障碍性不孕症的中药制剂及其制备方法 | |
CN100396308C (zh) | 治疗骨质疏松症的仙灵骨葆软胶囊及制备方法 | |
CN102552377A (zh) | 一种抗辐射损伤药物 | |
CN106860656A (zh) | 一种治疗骨质疏松症的中药组合物及其制备方法和应用 | |
CN105853689A (zh) | 青梅提取物在制备治疗骨质疏松保健品中的用途 | |
CN112137087A (zh) | 一种壮骨补钙的组合物、保健品及其制备方法 | |
CN110367537A (zh) | 一种调理更年期综合征的功能性食品及其制备方法 | |
CN113491757B (zh) | 一种中药组合物在制备防治骨质疏松症药物中的应用 | |
CN103251935A (zh) | 一种含有鹿茸的药用组合物及应用 | |
US11058737B2 (en) | Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females | |
CN102552386B (zh) | 一种抗骨质疏松的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210421 Address after: 054000 five kilometers away from the east exit of Xingtai City, Hebei Province (Nanhe Industrial Park) Patentee after: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Address before: 050035 No. 168 Haihe Road, Shijiazhuang hi tech Development Zone, Hebei, China Patentee before: HEBEI YUZHILIN BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a medicine composition for treating osteoporosis and a preparation method thereof Effective date of registration: 20210610 Granted publication date: 20160824 Pledgee: Baoding Qingyuan Rural Credit Union Co.,Ltd. Pledgor: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2021130000013 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20160824 Pledgee: Baoding Qingyuan Rural Credit Union Co.,Ltd. Pledgor: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2021130000013 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination for treating osteoporosis and its preparation method Granted publication date: 20160824 Pledgee: Handan Bank Co.,Ltd. Shijiazhuang High tech Zone Branch Pledgor: HEBEI YUZHILIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980036189 |